Export

ATC codes: J01DI04
Indication
Carbapenem-resistant Pseudomonas aeruginosa ICD11 code: MG50.80
INN
Cefiderocol
Medicine type
Chemical agent
Antibiotic groups
List type
Complementary
Formulations
Parenteral > General injections > IV: 1 g in vial (as sulfate toxylate) powder for injection
EML status history
First added in 2021
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Expert Committee recommendation
The Expert Committee recommended the inclusion of cefiderocol on the EML for treatment of adults with multi-drug resistant infections due to carbapenem-resistant Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa and endorsed cefiderocol as a Reserve antibiotic in the AWaRe classification. The Committee noted that cefiderocol is one of the few medicines that has activity against carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii, which are ranked as “Critical Priority” on the WHO Priority Pathogens List. Cefiderocol was shown to be non-inferior to carbapenems with regard to microbiologic/clinical response and mortality (with the possible exception of infections due to carbapenem-resistant Acinetobacter spp., where higher mortality has been observed in patients receiving cefiderocol) in settings where there are few alternatives for multidrug-resistant Gram-negative organisms producing metallo-betalactamases. The Committee highlighted the importance of antibiotic stewardship activities to assure appropriate use, while preserving access for patients in need of this medicine. Full details of the Committee's recommendation will be updated following publication of the technical report of the meeting.